On October 31, 2023 EORTC reported that Acute myeloid leukaemia (AML) is a blood cancer that predominantly occurs in older patients. Intensive chemotherapy regimens have been used for decades to treat patients regarded as sufficiently fit to tolerate this treatment (Press release, EORTC, OCT 31, 2023, View Source [SID1234636524]). Allogeneic haematopoietic cell transplantation following treatment with chemotherapy drugs can reduce the risk of a relapse, thus offering the primary curative approach. However, many older patients with AML treated with intensive chemotherapy die or cannot undergo allogeneic haematopoietic cell transplantation due to toxicity caused by intensive chemotherapy.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Hypomethylating agents are drugs that have significantly improved the prognosis of elderly patients regarded as unfit to receive intensive treatment. We hypothesised that replacing this intensive chemotherapy with a hypomethylating agent (decitabine) could improve outcomes of patients 60 years of age or older and fit to receive intensive chemotherapy. To investigate this hypothesis, the collaborative groups EORTC Leukaemia Group, GIMEMA and GMDS-SG joined forces to conduct the EORTC-1301-LG-AML21 phase III clinical trial (NCT02172872) in which we compared a 10-day decitabine monotherapy schedule with intensive chemotherapy in this patient population. The study was led by the EORTC Leukaemia Group and coordinated by Professor Gerwin Huls from University Medical Centre Groningen, Professor Michael Lübbert from the University Medical Centre Freiburg, and Professor Pierre Wijermans from the Haga Teaching Hospital (names of study coordinators provided in alphabetical order). Professor Adriano Venditti from the University of Rome Tor Vergata coordinated the GIMEMA activities.
The results, with 606 patients accrued at 54 centres in 9 European countries, were just published1 in one of the leading medical journals (The Lancet Haematology). They showed a comparable overall survival between the two treatment arms (HR 1.04, 95% CI 0.86-1.26; p-value 0.68). At 4 years, 26% of patients from the decitabine arm and 30% from the intensive chemotherapy arm were estimated to be alive. The proportion of patients who underwent allogeneic haematopoietic cell transplantation as a part of the study protocol was comparable as well (40% for decitabine, 39% for "3+7" at 4 years) and more than half of patients in both treatment arms underwent allogeneic haematopoietic cell transplantation at some timepoint. A notable difference between the treatment arms was observed regarding the incidence of severe adverse events during the treatment with decitabine as compared with intensive chemotherapy. Decitabine treatment showed lower incidences of severe infections (41% vs 53%), oral mucositis (2% vs 10%) and diarrhoea (1% vs 8%).